Trending Topic

Breast Cancer
29 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Endocrine therapy (ET) has changed the natural history of hormone receptor-positive (HR+) breast cancer (BC) and is the cornerstone of the treatment of HR+ BC. There are several ETs approved for the treatment of BC, including selective oestrogen receptor modulators (SERMs; tamoxifen), aromatase inhibitors (AIs; anastrazole, letrozole and exemestane) and selective oestrogen receptor degraders (SERDs; fulvestrant […]

Yann-Alexandre Vano, ESMO 2020 – Nivolumab and Ipilimumab or VEGFR Tyrosine Kinase Inhibitor in Naive Metastatic Kidney Cancer: The BIONIKK Trial

Yann-Alexandre Vano
Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Oct 1st 2020

Dr Yann-Alexandre Vano joins touchONCOLOGY to discuss the role of personalization of treatment in kidney cancer, and the major findings from the BIONIKK trial investigating nivolumab and ipilimumab as a first-line therapy for patients with kidney cancer. The late-breaking abstract ‘Results from the phase 2 BIOmarker driven trial with Nivolumab (N) and Ipilimumab or VEGFR tyrosine Kinase inhibitor (TKI) in naïve metastatic Kidney cancer (m-ccRCC) patients (pts): the BIONIKK trial’(LBA25) was presented at the Virtual 2020 ESMO Congress in September 2020.

Questions

  1. In which metastatic kidney cancer patients is nivolumab and ipilimumab indicated as first-line therapy, and what are the limitations of its use? (0:06)
  2. What were the aims and design of the BIONIKK trial? (2:00)
  3. What were the major findings of the trial? (3:49)
  4. What will be the impact of these findings on future personalization of treatment according to tumour molecular characteristics in kidney cancer? (6:06)
  5. What unanswered questions remain in the use of nivolumab and ipilimumab, and what future studies are planned? (8:30)

Speaker Disclosures: Yann-Alexandre Vano  has nothing to disclose in relation to this interview.

Support: Interview and filming supported by Touch Medical Media Ltd. The BIONIKK trial was sponsored by Association pour la Recherche des Thérapeutiques Innovantes en Cancérologie – Bristol Myers Squibb.

Filmed in coverage of the Virtual 2020 ESMO Congress.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied

This Functionality is for
Members Only

Explore the latest in medical education and stay current in your field. Create a free account to track your learning.

Close Popup